Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29194688 | 0.86 | BCHE (0.80) | BCHEKDM4EALDH1A1NPC1CHRM2 | |
| SCHEMBL9957662 | 0.85 | CNR1 (0.49) | BCHEKDM4EALDH1A1NPC1CHRM2 | |
| SCHEMBL16982017 | 0.84 | GAA (0.64) | BCHEKDM4EALDH1A1NPC1CHRM2 | |
| SCHEMBL8496610 | 0.82 | BCHE (0.79) | BCHEKDM4EALDH1A1NPC1CHRM2 | |
| SCHEMBL5177357 | 0.81 | BCHE (0.65) | BCHEKDM4EALDH1A1NPC1CHRM2 | |
| SCHEMBL18114970 | 0.81 | CHRM2 (0.77) | BCHEKDM4EALDH1A1NPC1CHRM2 | |
| SCHEMBL16980537 | 0.79 | GAA (0.67) | BCHEKDM4EALDH1A1CHRM2CHRM1 | |
| SCHEMBL18781451 | 0.79 | GAA (0.67) | BCHEKDM4EALDH1A1CHRM2CHRM1 | |
| SCHEMBL3581357 | 0.78 | KMT2A (0.61) | BCHEKDM4EALDH1A1NPC1CHRM2 | |
| SCHEMBL5947549 | 0.78 | BCHE (0.76) | BCHEKDM4EALDH1A1NPC1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218110-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218110-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218110-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | GABBR1, GABRA1, GABRA6 | BCHE 2166/4885KDM4E 2419/4885ALDH1A1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.